featured
177Lu-DOTA-TATE Plus Long-Acting Octreotide vs High‑Dose Long-Acting Octreotide for Newly Diagnosed, Advanced Grade 2–3, Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumours
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Lancet 2024 Jun 05;[EPub Ahead of Print], S Singh, D Halperin, S Myrehaug, K Herrmann, M Pavel, PL Kunz, B Chasen, S Tafuto, S Lastoria, J Capdevila, A García-Burillo, DY Oh, C Yoo, TR Halfdanarson, S Falk, I Folitar, Y Zhang, P Aimone, WW de Herder, D FeroneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.